RxSight’s guidance reset and stalled LDD placements create execution risk, but its sole FDA-approved adjustable IOL platform, Alcon alliance, and near-cash valuation offer asymmetric five-year upside.
Overview
RxSight is a commercial-stage ophthalmic device company whose Light Adjustable Lens (LAL) system allows surgeons to customize vision after cataract surgery, addressing a key limitation of fixed-power premium IOLs. The company earns revenue from high-margin lens consumables, LDD capital equipment, and collaboration payments. It is the only commercially available FDA-approved post-operatively adjustable IOL platform, supported by patents, PMA barriers, practice switching costs, and more than 300,000 procedures. The growth opportunity is meaningful: the U.S. premium cataract and refractive lens exchange market exceeds $1.5 billion, while the global market exceeds $3.5 billion. Yet execution has weakened: Q2 2026 revenue was $33.7 million, including $27.2 million in product sales and $6.5 million in Alcon collaboration revenue, versus $35.0 million of product revenue in Q2 2025; LDD placements were only 12 units. Management withdrew 2026 guidance during a commercial review. **The central near-term test is whether the new Customer Success Organization can lift utilization across 1,134+ installed LDDs.** The Alcon deal brings up to $200 million in milestones and royalties and targets a PCIOL launch in 2028. At $5.02, the shares trade near stated net cash per share; the report’s probability-weighted 2031 target is $29.51, with early-2027 guidance reinstatement and commercial stabilization as catalysts.